Evaluation and Optimization of the Administration of Recombinant Adeno-Associated Viral Vectors (Serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by Convection-Enhanced Delivery to the Striatum

被引：22

作者：

不详

机构：

[1] Department of Neurosurgery, Frenchay Hospital

[2] Clinical Sciences at North Bristol, University of Bristol

[3] Department of Neurology and Gene Therapy Center, University of Massachusetts, Worcester

来源：

HUMAN GENE THERAPY | 2011年 / 22卷 / 02期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1089/hum.2010.129

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Convection-enhanced delivery (CED) of recombinant adeno-associated virus (rAAV) vectors is a promising approach for delivery of therapeutic transgenes to the brain. In this study we have systematically examined vector dosing in vivo. Infusions of rAAV serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10 expressing an enhanced green fluorescent protein reporter gene were undertaken into the striatum of rats and pigs using CED. Vector distribution, as defined by the volume of distribution and number of transduced cells following each infusion, was determined using stereological methods. Immunohistochemistry was used to determine the transductional tropism of serotypes and to evaluate for the presence of immune cell infiltration into the brain. Vector distribution was highly variable between serotypes. Infusion rate had no significant effect on vector distribution or the occurrence of tissue damage. For serotypes 2/1, 2/2 and 2/rh10, as the vector concentration was increased beyond 10(12) vg/ml, no increase in vector distribution was observed. In contrast, for serotypes 2/rh8 and 2/9, retrograde axonal transport was observed above this threshold concentration. Cell transduction was principally neuronal for all serotypes and was associated with a low-level immune response. In planning clinical trials it is critical that these observations are considered in order to achieve optimal vector dosing.

引用

页码：237 / 251

页数：15

共 45 条

[11]

Davidson B.L., Stein C.S., Heth J.A., Martins I., Kotin R.M., Derksen T.A., Zabner J., Ghodsi A., Chiorini J.A., Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system, Proceedings of the National Academy of Sciences of the United States of America, 97, 7, pp. 3428-3432, (2000)

[12]

Eberling J.L., Jagust W.J., Christine C.W., Et al., Results from a phase i safety trial of hAADC gene therapy for Parkinson disease, Neurology, 70, pp. 1980-1983, (2008)

[13]

Erles K., Sebokova P., Schlehofer J.R., Update on the prevalence of serum antibodies (IgG and IgM) to adeno- associated virus (AAV), Journal of Medical Virology, 59, 3, pp. 406-411, (1999)

[14]

Felix B., Leger M.E., Albe-Fessard D., Et al., Stereotaxic atlas of the pig brain, Brain Res. Bull., 49, pp. 1-137, (1999)

[15]

Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A., Functional recovery in parkinsonian monkeys treated with GDNF, Nature, 380, 6571, pp. 252-255, (1996)

[16]

Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P., Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease, Nature Medicine, 9, 5, pp. 589-595, (2003)

[17]

Hadaczek P., Forsayeth J., Mirek H., Et al., Transduction of nonhuman primate brain with adeno-associated virus se-rotype 1: Vector trafficking and immune response, Hum. Gene Ther., 20, pp. 225-237, (2009)

[18]

Hadaczek P., Kohutnicka M., Krauze M.T., Et al., Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain, Hum. Gene Ther., 17, pp. 291-302, (2006)

[19]

Hadaczek P., Yamashita Y., Mirek H., Tamas L., Bohn M.C., Noble C., Park J.W., Bankiewicz K., The "Perivascular Pump" Driven by Arterial Pulsation Is a Powerful Mechanism for the Distribution of Therapeutic Molecules within the Brain, Molecular Therapy, 14, 1, pp. 69-78, (2006)

[20]

Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., Bland R.J., Young D., Strybing K., Eidelberg D., During M.J., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, Lancet, 369, 9579, pp. 2097-2105, (2007)

← 1 2 3 4 5 →